Clinical Trial: Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset

U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07324837) titled 'Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset' on Dec. 23, 2025.

Brief Summary: Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus injection of the recombinant non-immunogenic staphylokinase (Fortelyzin(R), LLC "SuperGene", Russia) or placebo.

Study Start Date: Feb. 01

Study Type: INTERVENTIONAL

Condition: Ischemic Stroke, Acute

Intervention: DRUG: non-immunogenic staphylokinase

The ...